Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 6/20 | 0.70 |
| ▸ | PRKCG | P05129 | 2/20 | 0.68 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.67 |
| ▸ | CETP | P11597 | 1/20 | 0.65 |
| ▸ | RELA | Q04206 | 1/20 | 0.65 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.65 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.65 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.65 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3790380 | 1.00 | NT5E (0.70) | NT5EPRKCGPRKCDCETPRELA | |
| SCHEMBL15713557 | 1.00 | NT5E (0.70) | NT5EPRKCGPRKCDCETPRELA | |
| SCHEMBL18710912 | 0.94 | NT5E (0.71) | NT5EPRKCD | |
| SCHEMBL3784133 | 0.94 | NT5E (0.71) | NT5EPRKCD | |
| SCHEMBL17128857 | 0.94 | NT5E (0.71) | NT5EPRKCD | |
| SCHEMBL17124241 | 0.92 | PRKCG (0.70) | NT5EPRKCGPRKCDCETPEGLN2 | |
| SCHEMBL16349462 | 0.92 | PRKCG (0.67) | NT5EPRKCGPRKCDCETPEGLN2 | |
| SCHEMBL15713556 | 0.91 | PRKCG (0.80) | NT5EPRKCGPRKCDCETPRELA | |
| SCHEMBL14344383 | 0.91 | PRKCG (0.80) | NT5EPRKCGPRKCDCETPRELA | |
| SCHEMBL3787219 | 0.91 | PRKCG (0.80) | NT5EPRKCGPRKCDCETPRELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087560-A1 | Leukemia; anticancer agents; antiproliferative agents | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2004-05-06 | — | — | US | claimed |
| US-6369109-B1 | Betulinic acid and derivatives thereof useful for the treatment of neuroectodermal tumor | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2002-04-09 | — | — | US | claimed |
| US-7858606-B2 | Triterpenoid derivatives | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2010-12-28 | — | — | US | disclosed |
| US-20040087560-A1 | Leukemia; anticancer agents; antiproliferative agents | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2004-05-06 | — | — | US | disclosed |
| US-6369109-B1 | Betulinic acid and derivatives thereof useful for the treatment of neuroectodermal tumor | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2002-04-09 | — | — | US | disclosed |
| EP-1124842-A1 | BETULINIC ACID AND DERIVATIVES THEREOF USEFUL FOR THE TREATMENT OF NEUROECTODERMAL TUMORS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000024762-A1 | BETULINIC ACID AND DERIVATIVES THEREOF USEFUL FOR THE TREATMENT OF NEUROECTODERMAL TUMORS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087560-A1 | Leukemia; anticancer agents; antiproliferative agents | MCL1, MKI67, CCNA1 | NT5E 3968/4885PRKCG 1274/4885PRKCD 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.